RSV Antibody Prophylaxis Needs for Extremely Preterm Infants in Their Second RSV Season

This cohort study examines children in British Columbia, Canada, born between 2013 and 2024 to assess whether use of monoclonal antibodies for a second respiratory syncytial virus (RSV) season is warranted for extremely preterm infants.

Corresponding Author: Pascal M. Lavoie, MDCM, PhD, British Columbia Children’s Hospital Research Institute, 950 W 28th Ave, Vancouver, BC V5Z 4H4, Canada (plavoie@bcchr.ca).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.